Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

NCT01854775 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01854775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01854775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
Lead sponsor
Gilead Sciences
Phase
Phase 2/3
Overall status
Completed
Start date
May 6, 2013
Completion date
June 18, 2025
Enrollment
129 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acquired immune deficiency syndrome (aids), hiv infections